Shares of NeuroPace, Inc. (NPCE) have gained 49.2% over the past four weeks to close the last trading session at $11.28, but there could still be a solid upside left in the stock if short-term price ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reporte The RNS System Post ...

NeuroPace Inc (NASDAQ:NPCE) reported a record revenue of $21.1 million for Q3 2024, marking a 28% increase compared to the same period last year. The company demonstrated disciplined operating ...

NeuroPace, Inc. NPCE shares rallied 5.1% in the last trading session to close at $6.35. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

NeuroPace (NPCE) announced completion of enrollment and implant procedures in its feasibility investigational device exemption, or IDE, study ...

Lake Street analyst Frank Takkinen reiterated a Buy rating on NeuroPace (NPCE – Research Report) yesterday and set a price target of $20.00. The company’s shares opened today at $11.09. Don't Miss our ...

Neuropace is listed on the CBOE trading with ticker code NPCE.US. It has a market capitalisation of $336.99m, with approximately 29.85m shares in issue. Over the last year, Neuropace share price ...